Physician profile
Lawrence Berson
NPI 1407942006
$3,170.94
in general payments reported to CMS, 2019-2025
23 companies · $315 in 2025
The $315 reported for 2025 was less than what a typical Foot and Ankle Surgery provider received nationally (typical 2025 total: $1,200).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,286 · 2020: $1,122 · 2021: $35.21 · 2022: $48.57 · 2023: $62.72 · 2024: $301 · 2025: $315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $679.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $678.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Wright Medical Technology, INC. | $1,122.24 | 2020 | |
| Avitus Orthopaedics, INC. | $900.00 | 2019 | |
| Stryker Corporation | $258.80 | 2023-2025 | Inbone, Easyfuse |
| Polaris Technology Solutions LLC | $135.27 | 2024 | |
| Pacira Therapeutics, INC. | $125.00 | 2019 | |
| Linvatec Corporation | $88.32 | 2019 | |
| Bioventus LLC | $69.22 | 2021-2024 | Exogen Ultrasound Bone Healing System |
| Depuy Synthes Sales INC. | $64.82 | 2019-2022 | |
| Davol INC. | $42.57 | 2024 | |
| Ferring Pharmaceuticals INC. | $37.57 | 2019 | |
| Kerecis Limited | $36.45 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Pacira Pharmaceuticals Incorporated | $34.48 | 2024 | Exparel |
| Smith+Nephew, INC. | $30.73 | 2025 | Pico |
| Medartis INC. | $29.91 | 2019 | |
| Djo, LLC | $28.50 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.04 | 2019 | |
| Dilon Technologies, INC. | $26.74 | 2025 | Hemoblast Bellows |
| Solventum Corporation | $25.55 | 2025 | V.A.C. Veraflo Cleanse Choice, Prevena, V.A.C.Ulta |
| Heron Therapeutics, INC. | $19.50 | 2025 | Zynrelef |
| Ibsa Pharma INC. | $18.66 | 2024 | Tirosint, Licart |
| Vertex Pharmaceuticals Incorporated | $18.43 | 2024 | |
| Dynasplint Systems INC. | $16.08 | 2024 | Dynasplint |
| Sanofi-Aventis U.S. LLC | $14.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Berson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.